SCIENTIFIC PROGRAMME

Thursday, April 2, 2020

 

09.00      

Registration Opens

11.00 – 11.10                  

Welcome Address

11.10 – 11.30 

TBA                 

11.30 – 13.00                  

Plenary Symposium 1: Emerging Concepts / New Agents

11.30 - 11.50                     

Myeloid immune checkpoint inhibition 

11.50 - 12.10                      

Neoadjuvant in melanoma: a new model for testing new strategies for improving efficacy

12.10 - 12.30                  

CXCR3 required for anti-PD-1 efficacy

12.30 - 12.50   

IL-15 for cancer therapy

12.50 - 13.10   

T cell bispecific antibodies (4-1BB and tumor antigen)

13.10 – 14.00                  

Lunch

14.00 – 15.30                  

Plenary Symposium 2: Microbiome and immunotherapy

14.00 – 14.25    

Microbiome and Immune System in Cancer

14.25- 14.40      

Potential of fecal microbiota for early-stage detection of colorectal cancer

14.40-14.55       

Crosstalk of the microbiome and epithelial cells

14.55 – 15.25    

Microbiome and Immunotherapy in Cancer

15.25 – 15.40    

Interplay of innate lymphoid cells and the microbiota

15:40- 15:55      

The role of microbiota in GvHD and complications of allogeneic SCT

16.00 – 16.30                  

Coffee Break

16.30 – 18.40                  

Plenary Symposium 3: Tumor microenvironment

 

16.30 - 16.50    

Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment

16.50 - 17.10    

Immunoscore as possible predictive marker of response to treatments

17.10 - 17.30    

Tumor intrinsic vs tumor extrinsic immune suppression 

17.30 - 17.50     

Multiplex in situ imaging and response to immunotherapy

17.50 - 18.10    

Cancer cell shapes tumor microenvironment

18.10 - 18.25                     

TBA

 

18.25 - 18.40                     

TBA

 

18.40 – 22.00                  

Welcome Reception and Poster Viewing (at the venue)

 

Friday, April 3, 2020

 

08.30 – 09.30                  

Plenary Symposium 4: Vaccine Therapy

08.30 - 09.00                      

Preventative cancer vaccines and shared antigens 

09.00 - 09.30                      

Multiple antigen-engineered DC vaccines promoting antitumor immunity in melanoma 

09.30 – 10.30                  

Pro & Contra Sessions on Critical Topics

09.30 – 10.00                     

TBA

 

10.00 – 10.30                     

TBA

10.30 – 11.00                  

Coffee Break

11.00 – 12.30                  

Plenary Symposium 5: Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

11.00 – 11.30                     

High dimensional immune profiling in immunotherapy clinical trials

11.30 – 12.00                     

FcR macrophage and hyperprogressor 

12.00 – 12.15                     

TBA

12.15 – 12.30                     

TBA

 

12.30 – 14.00                  

Lunch

14.00 – 15.00                  

Satellite Symposium (TBA)

 

15.00 – 15.45                   

Lifetime Achievement Award

15.45 – 16.15                  

Coffee Break

16.15 – 17.30                   

Plenary Symposium 6: “Lost in Translation”

16.15 – 16.45                     

TBA

16.45 – 17.15                     

TBA

17.15 – 17.30                     

TBA

17.30 – 18.30                  

Plenary Session 7: Young Researcher Session (from submitted abstracts)

17.30 – 17.45                     

TBA

17.45 – 18.00                     

TBA

18.00 – 18.15                     

TBA

18.15 – 18.30                     

TBA

19.30                                 

ITOC7 Conference Dinner

Saturday, April 4, 2020

08.00 – 09.00                  

Plenary Symposium 8: Cell Therapy in Solid Tumors

08.00 – 08.15                     

Challenges of T-cell therapy in solid tumors

08.15 – 08.30                     

On the topic of novel CAR formats for solid tumors 

08.30 – 08.45                     

Novel strategies to enable T cell therapy of cancer

08.45 – 09.00                     

CAR T cell therapy in non hematological pediatric cancer

09.00 – 10.30                   

Plenary Symposium 9: Cell Therapy in Haematologic Diseases

09.00 – 09.15                     

Cell therapy of hematological malignancies

09.15 – 09.30                     

CAR T cells for myeloma

09.30 – 09.45                     

Novel concepts for ALL cell therapy 

09.45 – 10.00                     

TBA

10.30 – 11.00                  

Coffee Break

11.00 – 12.45                   

Plenary Symposium 10: Combination Therapy

11.00 – 11.15                     

Combination of immune modulation and check point blockade

11.15 - 11.30                     

Chemotherapy and antiPD-1 neoadjuvant Triple negative breast Cancer

11.30 - 11.45                     

IL-1 B inhibition and anti-PD-1 

11.45 - 12.00   

PD1 and targeting adenosine pathway 

12.00 – 12.15                     

TBA

12.15 – 12.30                     

TBA

12.30 - 12.45                     

TBA

 

12.45 - 13.00                  

Best Poster Awards & Closing Remarks

 

13.00 – 14.00                   Lunch

© 2019 WMA GmbH - ITOC7     |     Data Protection Policy

  • Twitter - Grau Kreis